Cargando…

Transmembrane protease serine 5: a novel Schwann cell plasma marker for CMT1A

OBJECTIVE: Development of biomarkers for Charcot‐Marie‐Tooth (CMT) disease is critical for implementing effective clinical trials. The most common form of CMT, type 1A, is caused by a genomic duplication surrounding the PMP22 gene. A recent report (Neurology 2018;90:e518–3524) showed elevation of ne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Hongge, Davison, Matthew, Wang, Kathryn, Xia, Tai‐He, Kramer, Martin, Call, Katherine, Luo, Jun, Wu, Xingyao, Zuccarino, Riccardo, Bacon, Chelsea, Bai, Yunhong, Moran, John J., Gutmann, Laurie, Feely, Shawna M. E., Grider, Tiffany, Rossor, Alexander M., Reilly, Mary M., Svaren, John, Shy, Michael E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952315/ https://www.ncbi.nlm.nih.gov/pubmed/31833243 http://dx.doi.org/10.1002/acn3.50965

Ejemplares similares

PMP22 exon 4 deletion causes ER retention of PMP22 and a gain‐of‐function allele in CMT1E
por: Wang, David S., et al.
Publicado: (2017)

Unfolded protein response, treatment and CMT1B
por: Bai, Yunhong, et al.
Publicado: (2013)

Charcot-Marie-Tooth neuropathy score and ambulation index are both predictors of orthotic need for patients with CMT
por: Prada, Valeria, et al.
Publicado: (2021)

CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis
por: Fridman, V, et al.
Publicado: (2015)

Myelin protein zero mutations and the unfolded protein response in Charcot Marie Tooth disease type 1B
por: Bai, Yunhong, et al.
Publicado: (2018)

Treatment with IFB-088 Improves Neuropathy in CMT1A and CMT1B Mice
por: Bai, Yunhong, et al.
Publicado: (2022)

Validation of MRC Centre MRI calf muscle fat fraction protocol as an outcome measure in CMT1A
por: Morrow, Jasper M., et al.
Publicado: (2018)

Loss of Fig4 in both Schwann cells and motor neurons contributes to CMT4J neuropathy
por: Vaccari, Ilaria, et al.
Publicado: (2015)

Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT): A Protocol to Address Clinical Trial Readiness in CMT1A
por: Eichinger, Katy, et al.
Publicado: (2022)

Differential regulation of NAB corepressor genes in Schwann cells
por: Srinivasan, Rajini, et al.
Publicado: (2007)

Schwann cells ER-associated degradation contributes to myelin maintenance in adult nerves and limits demyelination in CMT1B mice
por: Volpi, Vera G., et al.
Publicado: (2019)

OBSTETRICS (C.M.T.)
Publicado: (1970)

A novel mouse model of CMT1B identifies hyperglycosylation as a new pathogenetic mechanism
por: Veneri, Francesca A, et al.
Publicado: (2022)

Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2A
por: Franco, Antonietta, et al.
Publicado: (2020)

Validation of the Italian version of the pediatric CMT quality of life outcome measure
por: Moroni, Isabella, et al.
Publicado: (2022)

Mutations in noncoding regions of GJB1 are a major cause of X-linked CMT
por: Tomaselli, Pedro J., et al.
Publicado: (2017)

Rate of Changes in CMT Neuropathy and Examination Scores in Japanese Adult CMT1A Patients
por: Kitani-Morii, Fukiko, et al.
Publicado: (2020)

An observational study of asymmetry in CMT1A
por: Pelayo-Negro, Ana L, et al.
Publicado: (2015)

HDAC-mediated Deacetylation of NF-κB is Critical for Schwann cell Myelination
por: Chen, Ying, et al.
Publicado: (2011)

Type II Transmembrane Serine Protease Gene Variants Associate with Breast Cancer
por: Luostari, Kaisa, et al.
Publicado: (2014)

CMT3 and SUVH4/KYP silence the exonic Evelknievel retroelement to allow for reconstitution of CMT1 mRNA
por: Yadav, Narendra Singh, et al.
Publicado: (2018)

Acute to Subacute Atraumatic Entrapment Neuropathies in Patients With CMT1A: A Report of a Distinct Phenotypic Variant of CMT1A
por: Chen, Zhiyong, et al.
Publicado: (2022)

Rare among Rare: Phenotypes of Uncommon CMT Genotypes
por: Gentile, Luca, et al.
Publicado: (2021)

Transmembrane serine protease 2 is a prognostic factor for lung adenocarcinoma
por: Schneider, Marc A., et al.
Publicado: (2022)

RESPIRATORY MEDICINE CMT (Concise Medical Textbook)
Publicado: (1981)

Caveats in the Established Understanding of CMT1A
por: Li, Jun
Publicado: (2017)

Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial
por: Pareyson, Davide, et al.
Publicado: (2011)

Thirty-Year Follow-Up of Early Onset Amyotrophic Lateral Sclerosis with a Pathogenic Variant in SPTLC1
por: Ajjarapu, Aparna, et al.
Publicado: (2023)

Comparative Study on Welding Characteristics of Laser-CMT and Plasma-CMT Hybrid Welded AA6082-T6 Aluminum Alloy Butt Joints
por: Xin, Zhibin, et al.
Publicado: (2019)

YAP and TAZ control peripheral myelination and the expression of laminin receptors in Schwann cells
por: Poitelon, Y, et al.
Publicado: (2016)

Interaction of Protein C Inhibitor with the Type II Transmembrane Serine Protease Enteropeptidase
por: Prohaska, Thomas A., et al.
Publicado: (2012)

Intracellular autoactivation of TMPRSS11A, an airway epithelial transmembrane serine protease
por: Zhang, Ce, et al.
Publicado: (2020)

Evolutionary history of type II transmembrane serine proteases involved in viral priming
por: Forni, Diego, et al.
Publicado: (2022)

Magnesium treatment on methylation changes of transmembrane serine protease 2 (TMPRSS2)
por: Fan, Lei, et al.
Publicado: (2021)

Association of the Transmembrane Serine Protease-2 (TMPRSS2) Polymorphisms with COVID-19
por: Posadas-Sánchez, Rosalinda, et al.
Publicado: (2022)

Type II Transmembrane Serine Proteases as Modulators in Adipose Tissue Phenotype and Function
por: Wu, Qingyu, et al.
Publicado: (2023)

LINC complex alterations in DMD and EDMD/CMT fibroblasts
por: Taranum, Surayya, et al.
Publicado: (2012)

Re-Introduction of Transmembrane Serine Residues Reduce the Minimum Pore Diameter of Channelrhodopsin-2
por: Richards, Ryan, et al.
Publicado: (2012)

Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2
por: Wu, Ching-Yuan, et al.
Publicado: (2020)

Docking study of transmembrane serine protease type 2 inhibitors for the treatment of COVID-19
por: Solanki, Naishadh
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qf7gtalh4gcmaefmbehv17phrf